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Introduction: One of the most often stated tenets of haemophilia care is that prophy-
laxis converts a person from a severe to a moderate phenotype. In this review, we 
argue that this is not an accurate assumption and that people on prophylaxis predomi-
nantly have factor VIII/IX levels in the mild range.
Moderate haemophilia and prophylaxis: People with moderate haemophilia, who are 
treating with on- demand regimens, experience joint bleeds and often develop sig-
nificant arthropathy. This is especially true for people with a baseline level of 1‒ 3 IU/
dl, as first reported 55 years ago, and confirmed in more recent studies. Evidence 
is emerging suggesting that people with severe haemophilia who are using prophy-
laxis have better musculoskeletal outcomes than people with moderate haemophilia 
treated episodically.
Trough levels: The debate around the optimum trough level whilst on prophylaxis is 
ongoing. It is not appropriate to extrapolate information about baseline levels to rec-
ommendations about target trough levels on prophylaxis because these are different 
situations. Studies are emerging that support higher target trough levels than previ-
ously used, but in spite of this, the aim of achieving zero bleeds remains elusive with 
both factor replacement and non- replacement therapies.
Conclusions: We recommend that people with moderate haemophilia, especially 
those with a baseline of 1– 3 IU/dl, should be offered prophylaxis based on the same 
criteria as people with severe haemophilia. Trough levels should be maintained above 
3 IU/dl or higher if a level of 3 IU/dl does not control breakthrough bleeding and 
prophylaxis should be tailored to the bleeding phenotype. This advice is in line with 
recently published guidelines from the World Federation of Haemophilia and the UK 
Haemophilia Centre Doctors’ Organisation.
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1  |  INTRODUC TION
Primary prophylaxis, with factor (F)VIII or FIX, is the recommended 
standard of care for young children with severe haemophilia. The aim 
of prophylaxis is to prevent bleeding episodes, especially haemar-
throses, with the long- term goal that the child reaches maturity with 
a normal musculoskeletal system. Prophylaxis is recommended to 
continue life- long.1– 4 In older people with haemophilia (PwH), sec-
ondary or tertiary prophylaxis is used to reduce bleeding episodes, 
limit progression of arthropathy and improve mobility.5– 7 Long- term 
studies support the efficacy of primary prophylaxis for preventing 
arthropathy in the large majority of children with severe haemo-
philia.8,9 However, delay in either starting prophylaxis or escalating 
to full dose is associated with musculoskeletal complications.10– 12 
Therefore, guidelines advocate initiating prophylaxis before or at the 
time of the first joint bleed. In line with guidelines, we recommend 
escalating prophylaxis rapidly to full dose and continuing this treat-
ment life- long1,2 although some clinicians escalate prophylaxis based 
on the pattern of bleeding.
Although the severity and progression of arthropathy are associ-
ated with the number of bleeds into a joint, this relationship is not al-
ways apparent and abnormalities can be demonstrated on magnetic 
resonance imaging (MRI) in joints with no recorded bleeds.9 This 
observation is attributed to subclinical bleeding, and whilst this is a 
plausible hypothesis, definitive evidence to confirm the assumption 
is awaited. The concept of subclinical bleeds contributes to the de-
bate over whether trough levels higher than 1 IU/dl would reduce ar-
thropathy by decreasing minor and unrecognised bleeding episodes.
2  |  SE VERE VERSUS MODER ATE 
HAEMOPHILIA
One of the most commonly stated tenets of haemophilia care is that 
prophylaxis converts the disorder from a severe to a moderate phe-
notype. This assumption is based, in part, on the original concept for 
prophylaxis which was to maintain a trough FVIII/IX above 1 IU/dl, in 
the range of moderate haemophilia.13 However, a comparison of the 
levels of FVIII/IX experienced by a person with severe haemophilia 
on prophylaxis and a person with moderate haemophilia treated on- 
demand shows that these are very different scenarios (Figure 1). In 
moderate haemophilia, the baseline level of FVIII is consistently low 
throughout the week. This means that the individual has no peaks 
of FVIII/FIX at the time of potential trauma or physical activity and 
so will not benefit from the additional protection that this would af-
ford. In contrast, a person with severe haemophilia on prophylaxis 
can tailor infusions so that they have normal FVIII/IX levels at the 
time of predictable haemostatic challenges and personalisation of 
care is routine practice for many people.14,15 It is important to recog-
nise that, in mild and moderate haemophilia A, stress or trauma can 
increase the baseline factor VIII and afford a temporary increased 
level of protection. This is not the case in haemophilia B.
A person on standard prophylaxis would expect to have a FVIII 
level above 5 IU/dl most of the time with levels only falling into 
the moderate range during the latter part of the second day and 
night. For example, in severe haemophilia treated with an infusion 
of 30 IU/kg on alternate days using a FVIII concentrate that has a 
half- life of about 12 h one would expect to spend more than 50% of 
the time with a level above 5 IU/dl. If treatment was with 15 IU/kg 
daily, to have more regular peaks, then FVIII would be above 5 IU/
dl for more than 85% of the time. In contrast, moderate haemophilia 
treated on- demand will be associated with a FVIII/IX level below 
5 IU/dl for prolong periods of time and higher levels will occur only 
at the times of intermittent treatment or minor increases seen at the 
time of stress. In effect, therefore, prophylaxis converts severe hae-
mophilia to mild rather than moderate haemophilia for significant 
amounts of time and results in FVIII/FIX levels substantially higher 
than 5 IU/dl for most of the week. Indeed, a person with moderate 
haemophilia who has a baseline of 1 IU/dl will have lower FVIII/FIX 
levels than a person with severe haemophilia on prophylaxis at all 
times except when treating a bleed.
In most haemophilia centres, prophylaxis is more likely to the of-
fered for severe haemophilia than for moderate. The reasons for this 
are complex but may relate to the assumption that moderate hae-
mophilia protects against arthropathy in a similar way to prophylaxis 
in severe haemophilia. If moderate haemophilia was phenotypically 
F I G U R E  1  Factor levels in moderate 
haemophilia and severe haemophilia on 
prophylaxis with trough level at 2 IU/
dl. Schematic representation of the time 
spent at different factor levels comparing 
(A) moderate haemophilia treated 
episodically and (B) severe haemophilia 
on prophylaxis. At all times, the person 
with severe haemophilia has higher factor 
levels and spends the majority of time 
with a level in the mild range. The y- axis is 
arbitrary
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similar to severe haemophilia on prophylaxis, arthropathy should be 
uncommon and annualised bleed rates (ABR) should be low. This as-
sumption, however, is not correct and this has been known for more 
than 50 years. A seminal paper published in 1965 described the 
experience of haemophilia care in Sweden before coagulation fac-
tor concentrates were routinely available.13 People with a baseline 
FVIII/IX <1 IU/dl had median (IQR) joint score of 12 (9- 16) demon-
strating significant arthropathy. Importantly, people with a baseline 
FVIII/IX levels 1– 3 IU/dl also had abnormal joint scores with a me-
dian (IQR) 8, (6- 11) demonstrating that this level of FVIII/IX was not 
protective against arthropathy. If the baseline FVIII/IX was >3 IU/dl, 
the joint score was zero in all but one case (Figure 2). It is important 
to note, however, that the joint scoring system used in this study was 
relatively insensitive and so would not have identified less severe 
joint pathology. This finding has been replicated recently in a cohort 
of people with haemophilia in Pakistan who had minimal access to 
FVIII concentrate. At an average age of 16 years, the Haemophilia 
Joint Health Score (HJHS) was median (IQR) 24 (16– 48) in severe 
haemophilia and 18 (5– 30) in the moderate group.16 It is clear that 
moderate haemophilia, in people who do not have access to coagula-
tion factor concentrates, is not protective against arthropathy.
This raises the question of whether people with moderate hae-
mophilia who have access to FVIII/IX would be protected against 
arthropathy because early treatment of bleeds might prevent syno-
vitis and inflammatory changes. This question was addressed in a UK 
Haemophilia Centre Doctors’ Organisation (UKHCDO) investigation 
of the long- term joint outcomes of people registered on the UK 
National Haemophilia Database. The moderate haemophilia group 
had a median (IQR) baseline FVIII level of 2 (1- 3) IU/dl and so were 
at the lower end of the moderate range. In the group born between 
1976 and 1996, the HJHS was found to be increased to a similar level 
in people with both severe and moderate haemophilia, irrespective 
of whether they were being treated on- demand or with tertiary pro-
phylaxis.17 This study confirmed findings in the Netherlands where 
it was shown that by the age of 40 years, moderate haemophilia was 
associated with a median HJHS of 8 if the FVIII was ≤2 IU/dl or the 
first joint bleed had occurred before the age of 5 years, and in this 
group, 25% of people had a joint score >12. Even those with FVIII 
>2 IU/dl or with a first haemarthrosis after the age of 5 years, 25% 
had a joint score of ≥8.18 These studies demonstrate that access to 
FVIII concentrate does not prevent arthropathy in moderate haemo-
philia and that by middle age joint pathology is common.
In the UKHCDO study, children with severe haemophilia born 
between 1996 and 2015, when prophylaxis was routine care in the 
UK, had a median (IQR) HJHS of 0 (0– 1) demonstrating excellent 
outcomes across all UK haemophilia centres.17 This finding relates 
to a time when UK practice was to initiate prophylaxis at the latest 
after the first joint bleed and to maintain a trough FVIII level of 
about 1 IU/dl or higher if breakthrough bleeds occurred.3 In con-
trast, children with moderate haemophilia born during the same 
period of time had a median (IQR) HJHS of 3 (0– 9) demonstrating 
significant arthropathy in more than 25% of children.17 The reason 
for the higher HJHS in children with moderate haemophilia cannot 
be known for certain but a plausible explanation is that they started 
prophylaxis later, and possibly less intensively, than the severe co-
hort, potentially because there was an assumption that they would 
be less prone to developing arthropathy. In addition, it is possible 
that subclinical bleeds may have affected children with moderate 
haemophilia more than those with severe haemophilia on prophy-
laxis, who would experience a peak level every other day, and this 
may have contributed to the joint damage. It appears that people 
with moderate haemophilia need to experience more bleeds than 
those with severe haemophilia and, in some cases, need to develop 
evidence of arthropathy before they have the opportunity to re-
ceive prophylaxis.
The pattern of bleeding in people with different severities of hae-
mophilia was addressed in a study designed to investigate whether 
the traditional classification of the severity of haemophilia remained 
relevant.19 The authors questioned whether the approach to severe 
and moderate haemophilia (early prophylaxis and close monitoring 
versus mainly on- demand and monitored less often) was justified. 
The group reported that people with moderate haemophilia and a 
baseline FVIII level of 1– 2 IU/dl had a median annualised joint bleed 
rate (AJBR) of about 5.5, despite 35% being on prophylaxis. As the 
baseline level increased from 2 to 3 IU/dl, the AJBR fell rapidly to 
about 2 and between 3 and 5, and there is a further decline to an 
AJBR of about 1. The AJBR did not approach zero until the baseline 
level reached 12 IU/dl. The AJBR for severe haemophilia could not 
be assessed in the study because >90% of this group were taking 
prophylactic treatment; however, it is known that people with se-
vere haemophilia who are not on prophylaxis often experience more 
than 20 bleeds a year.20,21 These data show that moderate haemo-
philia, especially with a baseline FVIII level between 1 and 3 IU/dl, is 
F I G U R E  2  Haemophilic arthropathy in people with haemophilia 
reported in Sweden in 1965. Box plots are derived from data 
available in Ahlberg13 figure 17 page 33. In the group >3 IU/dl, one 
person had a joint score of 3 and in all others the score was zero. 
The joint score used was not sensitive to soft tissue changes, and 
the results cannot be compared to HJHS
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associated with a significant number of joint bleeds each year and it 
is not surprising, therefore, that progressive arthropathy is seen.17– 19
These studies demonstrate that the definition of moderate hae-
mophilia encompasses a wide range of bleeding phenotypes and 
people with a baseline level of 1– 3 IU/dl have a different pattern 
of bleeding and joint scores to those with levels 3– 5 IU/dl. This was 
also seen in the joint scores in the early experience from Sweden 
(Figure 2).13 This suggests that a classification of moderate haemo-
philia that spans 1– 5 IU/dl might be too broad and potentially leads 
to a tendency to underestimate the severity of haemophilia in peo-
ple are at the lower end of the moderate range.
3  |  WHO SHOULD BE OFFERED 
PROPHYL A XIS?
In our opinion, the conclusion to be drawn from these data is that 
people with moderate haemophilia, and especially those with base-
line levels between 1 and 3 IU/dl, should be offered prophylaxis if 
they experience any joint or other clinically significant bleeds. This 
was also the conclusion reached by a Dutch group who summed up 
by stating ‘treatment decisions, such as starting prophylaxis, should 
therefore be tailored according to bleeding pattern rather than …. 
residual clotting factor levels’.19 UKHCDO has recently revised its 
prophylaxis guidelines and now recommends that children with 
moderate haemophilia and baseline levels between 1 and 3 IU/dl 
should be considered for primary prophylaxis and that all people 
with haemophilia, irrespective of baseline FVIII/IX, should be con-
sidered for prophylaxis after the first joint bleed to reduce the risk of 
developing arthropathy.2 This recommendation is also made by the 
World Federation of Haemophilia in their recently updated guide-
lines ‘Prophylaxis is the standard treatment for many people with 
haemophilia, not only those with severe disease but also those with 
moderate deficiency, irrespectively of the hemophilia type, ideally 
initiated before any bleeding episode’. (https://onlin elibr ary.wiley.
com/doi/epdf/10.1111/hae.14046) and in a supporting editorial.22
The target trough level for prophylaxis in moderate haemophilia 
is not known, and it seems illogical to aim for a higher trough than in 
severe haemophilia. The risk of break through bleeds is associated 
with time spent at low levels rather trough level23 and so returning 
to a baseline of 3 IU/dl for short periods of time may not be a signifi-
cant risk. This question will need to be addressed as experience with 
prophylaxis in moderate haemophilia increases.
In addition, we recommend that moderate haemophilia should 
be followed up by specialist physiotherapists in the same way and 
with the same frequency as severe haemophilia. This is especially 
important in young children so that subtle signs of arthropathy can 
be detected even if overt clinical bleeds have not been reported. 
Children with moderate haemophilia who have signs of joint pathol-
ogy should be offered prophylaxis.
4  |  WHAT TROUGH LE VEL S ARE 
REQUIRED DURING PROPHYL A XIS?
It is important not to confuse baseline FVIII/IX levels with trough 
levels on prophylaxis because these are very different measures. A 
paper investigating baseline levels19 has been used to argue in fa-
vour of aiming for trough levels on prophylaxis of about 12 IU/dl; 
however, it is not justified to extrapolate data derived from baseline 
F I G U R E  3  Factor levels in mild haemophilia and severe haemophilia on prophylaxis with trough level at 12 IU/dl. Schematic 
representation of the time spent at different factor levels comparing (A) mild haemophilia with a baseline level of 12 IU/dl treated 
episodically and (B) severe haemophilia on prophylaxis with a target trough level of 12 IU/dl. At all times, the person with severe haemophilia 
has a higher level and spends the majority of time with a level above 20 IU/dl. Scenario (A) is similar to the situation with Emicizumab and 
gene therapy achieving a level of 12 IU/dl. The difference in area under the curve comparing scenario a and b can be seen in the shaded 
areas for the time above 12 IU/dl plus the first treatment and the time between 20 and 12 IU/dl shown in black for the second two 
treatments. The area under the curve is substantially higher for the prophylaxis scenario. The y- axis is arbitrary
    |  5COLLINS et aL.
FVIII levels in this way and the authors did not draw this conclu-
sion. A baseline of 12 IU/dl and a trough of 12 IU/dl are different as 
shown in Figure 3, and this difference is emphasised further when 
FVIII/IX area under curve (AUC) is considered. A baseline of 12 IU/
dl has an AUC of 12 times 168 h whereas as a prophylaxis with a 
trough of 12 IU/dl has this minimum AUC plus that associated with 
the higher levels. If a trough level of 12 IU/dl was targeted, the in-
dividual would spend a substantial amount of time with their FVIII/
IX above 20 IU/dl. It is important to recognise that a baseline FVIII 
of 12 IU/dl is likely also to increase at the time of stress or trauma 
and increase the AUC. To inform decisions about appropriate target 
trough levels on prophylaxis, studies that investigate this question 
directly are required.
Valentino et al used pharmacokinetic- guided dosing to target a 
trough FVIII level of 1 IU/dl and compared this to ‘standard prophy-
laxis’ of 20– 40 IU/kg on alternate days. The target trough FVIII level 
of 1 IU/dl was successful achieved in the PK- guided arm and the me-
dian trough FVIII in the standard care arm was 3 IU/dl. The median 
ABR (IQR) was 2 (0– 4.9) in the PK- guided arm and 1 (0– 2.5) in the 
standard arm (p = 0.15), hinting that a trough of 3 IU/dl may give 
marginally better protection against bleeding than a trough of 1 IU/
dl.24. In the pivotal study of rFVIII- Fc, one arm individualised dosing 
to achieve a trough level of at least 1– 3 IU/dl. The mean (negative 
binomial 95% CI) ABR in that arm was 2.9 (2.3– 3.7), but there was no 
control group to compare with.20
The only study that directly compares two target trough levels is 
the PROPEL study. This study used pharmacokinetic- guided dosing 
with a pegylated rFVIII to target trough levels of 1– 3 or 8– 12 IU/dl. 
The target trough levels were achieved, and in the 1– 3 IU/dl group, 
the mean (Poisson's SD) of all bleed ABR was 3.6 (7.5) compared 
to 1.6 (3.4) in the 8– 12 IU/dl arm. More people had zero bleeds in 
6 months in the 8– 12 IU/dl group compared to the 1– 3 IU/dl group, 
62% vs. 42%, but this was not statistically significant (p = .055). In a 
subgroup analysis of people who were able to follow the protocol 
closely, the proportion of people with zero bleeds was 67% and 40% 
in the 8– 12 and 1– 3 IU/dl groups, respectively (p = .02).25 A post hoc 
analysis of another study suggested that most benefit in reducing 
the ABR on prophylaxis was derived by increasing the FVIII level to 
between 1 and 3 IU/dl but higher levels were required to achieve 
zero bleeds.26
A study of pegylated FIX randomised people with haemophilia 
B and a baseline FIX ≤2 IU/dl to on- demand treatment or weekly 
infusions of 10 IU/kg or 40 IU/kg. The participants were blinded to 
the dose of FIX and so would not have been influenced by this when 
reporting bleeds. The average trough levels achieved were 8.5 and 
27.3 IU/dl in the 10 and 40 IU/kg arms, respectively. The all bleed 
ABR was median (IQR) 15.6 (9.6– 26.5) in the on- demand group and 
2.9 (1.0– 6.0) and 1.0 (0.0– 4.0) in the 10 and 40 IU/kg arms, respec-
tively. Although this was not a study that targeted a specific trough 
level, it gives some indication of the ABR achievable with this product 
at two different trough levels compared to on- demand treatment.27
Achieving a trough FVIII level of 12 IU/dl may not be feasible in 
some cases, even using enhanced half- life FVIII products. Adherence 
and venous access issues may influence this. In the PROPEL study, 
some subjects needed to infuse daily to achieve a trough of 12 IU/dl 
and not all subjects could adhere to the regimen. The difference be-
tween clinical studies and real life needs to be considered. Achieving 
troughs of 12 IU/dl is much more feasible with enhanced half- life 
FIX.
Overall, these data support the view that higher trough levels 
are associated with fewer bleeds although it appears to be difficult 
to achieve an ABR of zero even with very high troughs. It must be 
recognised that bleed rates are patient reported and there is the po-
tential for misclassification of events, especially if the person has 
significant arthropathy. Tailoring the trough level to minimise bleed-
ing in individuals continues to be the practice of choice. Revised 
UKHCDO guidelines recommend aiming for a trough level of at least 
3 IU/dl or higher if necessary to prevent bleeding.2
5  |  TRE ATMENT WITH NON- 
COAGUL ATION FAC TOR REPL ACEMENT 
THER APIES
Although comparing ABRs at various FVIII/FIX baseline levels with 
those associated with trough levels on prophylaxis is not comparing 
like with like, the situation with other treatment strategies is differ-
ent. Emicizumab is associated with a constant level of haemostatic 
cover28 and so is more analogous to the baseline situation described 
by den Uijl and colleagues.19 This is also the case for other treatment 
strategies that are undergoing clinical trials such as inhibition or sup-
pression of inhibitors of coagulation29 and gene therapy.30,31
In the HAVEN 3 study, emicizumab was associated with a median 
(IQR) ABR of 1.5 (0– 4.3) in people who had been taking prophylaxis 
previously. Achieving zero bleeds remained challenging with 55.6% 
(95% CI 42.5– 68.1) reaching this target, similar to that achieved in 
the 10– 12 IU/dl FVIII trough arm of the PROPEL study.25 The study 
reports a treated bleed ABR of 1.5 (95% CI, 0.9– 2.5) and 1.3 (0.8– 
2.3) in the once a week and once every 2 weeks emicizumab arms, 
respectively, compared to 38.2 (22.9– 63.8) in the no prophylaxis 
group.28 This result is similar to those achieved with FVIII/FIX re-
placement at higher trough levels.
In an open- label observational study of antithrombin suppression 
with fitusiran published in abstract form, the ABR was 1.0 for both 
inhibitor and non- inhibitor groups. The outcomes of the phase 3 trial 
are awaited, but these early results are similar to those achieved by 
emicizumab and FVIII/FIX aiming for higher trough levels. In a gene 
therapy study of severe haemophilia A, the treated bleed rate ap-
proached zero at a FVIII level of about 12– 15 IU/dl,30 very similar to 
the findings of den Uijl et al. investigating baseline levels,19 although 
numbers are very small.
Gene therapy, emicizumab and inhibition of inhibitors are not 
associated with peak levels as would be seen with FVIII/FIX pro-
phylaxis. The consequences of not receiving regular peaks on long- 
term outcomes such as joint status are not well described, although 
one study suggested a possible protective effect on reducing ABR.32 
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Some people with haemophilia may wish to retain the ability to tailor 
levels to life style and have access to peak levels at a time of their 
choosing using standard FVIII/FIX prophylaxis.
6  |  CONCLUSIONS
In conclusion, we draw a distinction between studies that report 
baseline FVIII/FIX data and those that target specific trough levels 
on prophylaxis and suggest that data cannot be extrapolated from 
one situation to the other. Prophylaxis should be offered to all peo-
ple with haemophilia, irrespective of baseline level, if they experi-
ence joint or other clinically significant bleeds. Primary prophylaxis 
should be considered for children with moderate haemophilia, es-
pecially those with baseline FVIII/FIX levels between 1 and 3 IU/
dl. These recommendations align with recently published UKHCDO 
guidelines2 and are the conclusion of other groups.19 Data are 
emerging to support higher trough levels for people on prophylaxis, 
but more studies are required to define the optimum level and this 
will inevitably vary between individuals. Tailoring to the individual 
pattern of bleeding remains critically important and often over- rides 
considerations of trough FVIII/IX levels.2,12,18,19 High- quality studies 
to compare long- term outcomes between people treated with FVIII/
FIX prophylaxis and non- replacement therapies are required. The 
current classification of moderate haemophilia covers a very wide 
phenotype and may need to be reconsidered.
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